

Guidelines

Growth Grant Funding Agreement



Version > V01

Date > October 2015

CallaghanInnovation

BUSINESS TECHNOLOGY SUCCESS

Contents

1.	Introduction.....	3
1.1.	Purpose.....	3
2.	Agreement.....	3
2.1.	Requirements.....	3
2.1.1.	Growth funding.....	4
2.1.2.	Project management.....	5
2.1.3.	Government requirements	5
2.1.4.	Suspending, terminating or changing	6
2.1.5.	Contract extensions	7
3.	General information.....	7
	Appendix: Example of Funding Agreement for R&D Growth Grant	8

1. Introduction

1.1. Purpose

Callaghan Innovation manages the Business Research and Development (R&D) Grants scheme on behalf of Government. The objective of these grants is to increase investment by New Zealand businesses in research and development to support long term economic growth.

To enable the assessment of proposals for Business R&D Grants, each application decision and allocation is assessed and reviewed.

The Growth Grant is designed to:

- > Develop recipients in to stable and substantial Research and Development (R&D) performers
- > Develop recipients' R&D expertise and understanding aimed at development of new or substantially improved devices, products, processes, systems or services

This document provides a high level summary of the funding agreement for Growth Grants:

- > To businesses and account managers
- > To assist businesses and account managers understand the intent of agreement
- > To identify major implications for businesses applying for a Growth grant

Detail on specific contractual issues is detailed in the funding agreement which should be referred to by Account Managers and businesses as needed.

2. Agreement

The funding agreement is a legal contract between Callaghan Innovation and the business seeking a Growth grant.

The agreement:

- > Sets out responsibilities and how the programme is governed
- > Comprises a series of standard clauses
- > Includes a schedule relevant to the particular Growth application which tailors the standard clauses to a particular Growth application by
 - Including details of the business
 - Including details of the approval - the funding amount; start and end dates, etc.
 - Merging the business application for a growth grant with the funding agreement
 - Containing special contract conditions added by Callaghan Innovation to mitigate any perceived risks

2.1. Requirements

The funding agreement addresses a number of issues including:

- > Use of Growth funding
- > Sound project management

- > Meeting government's requirements as laid out in the ministerial direction
- > Suspending or terminating the funding agreement
- > Contract extensions

The Funding agreement along with the schedules is the entire agreement between the business and Callaghan Innovation.

2.1.1. Growth funding

Detail and use of the growth funding and co-funding from the business is outlined in the table below:

- > Callaghan Innovation will provide funding for a business's Research and Development (R&D) program:
 - Will pay 20% of the business's eligible R&D spend up to \$25m over 5 years
 - The amount paid is up to a maximum of \$5m per year
 - Any intellectual property developed in the R&D program will belong to the business
 - The business must acknowledge Callaghan Innovation when reporting publically, the results and outputs of the R&D program
- > Funding payments:
 - Callaghan will pay out 90% of satisfactory invoices and hold back 10% as retention, at the end of each quarter
 - At the end of each year
 - The business determines their actual R&D spend which needs audited accounts to be independently verified.
 - An invoice is issued to Callaghan Innovation for the retention with any adjustments and accompanied with a review certificate
- > Eligible R&D expenditure is defined in the Accountancy Standard IAS38 with the exception of exclusions which are ineligible as follows:
 - R&D capitalised as an intangible asset
 - All R&D undertaken outside NZ
 - All R&D funded through an enforceable levy, or paid by you to another entity
 - R&D funded by a grant or other payment from an entity that is not part of the same consolidated group of entities
 - Specific exclusions in the Ministerial Direction Guideline
- > The Growth grant does not cover R&D costs incurred before the contract start-date or after the contract end date

2.1.2. Project management

The requirements for sound project management are outline in the table below:

- > The business must employ sound project management techniques to manage the Research and Development (R&D) program and deliver the results identified in their application for Growth funding
- > There must be formal arrangements with all parties involved in the R&D Growth; including ownership of IP
- > The business must comply with all relevant legal, regulatory and compliance requirements
- > The business is required to inform Callaghan Innovation of any government funding for the R&D program in addition to that disclosed in the application
- > The business must record how the funding has been used on the program (e.g. payslips, invoices and receipts). This is to allow Callaghan Innovation to audit the use of funds under the funding agreement and an audit can be undertaken at any time during the program and up to two years after the contract end date
- > If the agreement is breached by the business Callaghan Innovation may require remediation (e.g. repayment of funding) or in more serious situations, negotiate a variation or termination of the agreement
- > The business must immediately advise Callaghan Innovation of any significant risks that impact on the business's ability to:
 - Undertake the R&D growth
 - Deliver the results
 - Or realise the anticipated benefits to NZ including on-going R&D activity in NZ.

2.1.3. Government requirements

There is a requirement to meet the Government's requirements as laid out in the Ministerial Direction as outlined in the table below.

- > Callaghan Innovation is required to release publicly, information relating to the agreement, including:
 - The business name
 - Contract ID
 - Title of the program
 - The type of funding provided
 - The relevant sector
 - Amount of funding
 - Year of approval
 - Aggregated statistics relating our portfolio of contracts

- > Callaghan Innovation may release information to its appointed agents and advisors, MBIE and NZTE, on an as-required basis. Callaghan Innovation may also be legally required to release information, parliamentary questions and ministerial requirements (e.g. under the Official information Act (OIA)). Callaghan Innovation will consult the business before responding to an OIA request.
- > Callaghan Innovation may review a business's R&D Program and conduct this during the contract or up to two years after the contract has ended:
 - To determine the performance of the grants-scheme
 - To identify potential improvements
- > Callaghan Innovation may also ask a business to complete a survey. These are used to determine:
 - The impact of the Growth Grant on the business which assists Callaghan Innovation report on performance of the grants scheme

2.1.4. Suspending, terminating or changing

The funding agreement can be suspended, terminated or changed under the conditions set out in the table below.

- > The funding agreement can be terminated by either party at any time by giving 2-months' notice. If either party breaches the agreement, the other party can terminate the agreement immediately
- > If the funding provided to Callaghan Innovation for the Growth Grant, is materially altered then Callaghan Innovation may reduce or suspend funding or terminate the agreement
- > Callaghan Innovation may terminate this agreement if:
 - The funding is not used correctly
 - Dishonest claims are made
 - False information is provided
 - The business is bankrupt or insolvent
 - The business enters into a contract that materially reduces the benefits to NZ without approval from Callaghan Innovation (Benefits to NZ are reduced when the business is unlikely to develop an on-going Research and Development (R&D) activity in NZ, the scale of the R&D program reduces, or the R&D is undertaken overseas)
- > If the agreement is terminated the business may be required to repay some, or all, of the funding
- > A change event occurs when:
 - Either party cannot meet their obligations
 - The ownership of the business changes which reduces the benefits to NZ including future R&D activities in NZ
 - The actual R&D spend is significantly different from the forecast

- > Callaghan Innovation will attempt to negotiate a variation to the agreement, otherwise either party may terminate the agreement where benefit to NZ is reduced, the business may have to repay the Grant Funding.

2.1.5. Contract extensions

Two years after the contract start date the business can apply for an extension:

- > This can be for a two-year contract extension
- > It will be approved if the business meets the relevant criteria.

The extension will be implemented as a variation to the agreement

3. General information

Additional information for the growth funding agreement:

- > Applicants accept the standard funding agreement when they apply for Growth funding
- > Businesses applying for Growth funding are advised to read the contract before they submit their application for a Growth grant and applicants are bound to accept this standard contract
- > The application provided by the business for Growth funding is part of the funding agreement
- > The schedule tailors the standard clauses to a particular Growth application by including:
 - The business details
 - Details of approval (i.e. funding amount, start and end dates, etc.)
 - Details any changes to Growth costs.

Appendix: Example of Funding Agreement for R&D Growth Grant

Date:

Funding Agreement for an R&D Growth Grant

between

Callaghan Innovation

and

Contract number:

Signed for and on behalf of **Callaghan Innovation**:

Signature:

Name:

Date:

Title:

In the presence of:

Signature:

Name:

Title:

Signed for and on behalf of

Signature:

Date:

Name:

Title:

In the presence of:

Signature:

Name:

Title:

CONTENTS

1. OUR OBLIGATIONS	12
2. FUNDING	13
3. ELIGIBLE R&D EXPENDITURE	13
4. INTELLECTUAL PROPERTY	14
5. AUDIT	15
6. REPORTING	16
7. REVIEW.....	17
8. CONFIDENTIALITY.....	ERROR! BOOKMARK NOT DEFINED.
9. CHANGE EVENTS.....	ERROR! BOOKMARK NOT DEFINED.
10. TERMINATION AND REDUCTION OR SUSPENSION OF FUNDING.....	19
11. RETURN AND REPAYMENT OF FUNDING	20
12. INDEMNITY	21
13. ENTIRE AGREEMENT	22
14. NOTICES	22
15. SURVIVAL OF CLAUSES	22
16. FORCE MAJEURE	22
17. NATURE OF RELATIONSHIP.....	22
18. VARIATIONS	23
19. ASSIGNMENT & TRANSFER	23
20. GOVERNING LAW	23
21. WAIVER.....	24
22. PARTIAL INVALIDITY	24
SCHEDULE AGREEMENT DETAILS – R&D GROWTH GRANT.....	25

This Agreement is made on

between Callaghan Innovation, a Crown entity established under the Callaghan Innovation Act 2012 ("Callaghan Innovation")

and ("you" or "your")

together referred to as "**we**", "**us**", or "**our**".

BACKGROUND

- A. Callaghan Innovation invests in research, development, and commercialisation activities and capabilities to increase New Zealand businesses' investment in research and development to support long term economic growth. Research and development (R&D) growth grants are given to businesses with experience in investing in research and development in order to provide those businesses with a rule-based, market-led incentive to increase their investment in research and development.
- B. You have applied to Callaghan Innovation for a funding grant to cover a portion of the costs of your research and development programme ("**Programme**") for a minimum of 3 years. The Programme is referred to in the schedule to this Agreement ("**Schedule**") and described in detail in your application and your research and development plan ("**Application**").
- C. Your Application has been approved, and Callaghan Innovation will provide the funding specified in the Schedule to enable you to carry out the Programme ("**Funding**").
- D. The purpose of this Agreement is to govern the investment of the Funding in the Programme by:
 - (a) setting out Callaghan Innovation's expectations and requirements as to your ongoing investment in the Programme;
 - (b) acknowledging that we have a mutual interest in ensuring, and being able to demonstrate, that the Programme is aligned with priorities established by the Government from time to time, and enhances New Zealand's economic position through increasing research and development activity in New Zealand; and
 - (c) setting out, amongst other things, the circumstances in which Callaghan Innovation may audit, review, suspend, reduce or terminate payment of the Funding or reduce the amount of Funding paid to you.
- E. We intend, acting reasonably and in good faith, to work together in order to satisfy and meet the requirements of this Agreement and to ensure the greatest possibility of success of the Programme.
- F. You will, 2 years after the contract start date specified in the Schedule ("**Contract Start Date**"), be able to apply for a 2 year extension of your funding grant, and will receive an extension if you meet the relevant criteria. The extension will be implemented by way of a variation to this Agreement.

1. OUR OBLIGATIONS

- 1.1. We undertake to pay you as per Funding in accordance with clause 2, an amount that is 20% of your eligible R&D expenditure as defined in clause 3 ("Eligible R&D Expenditure").
- 1.2. You undertake to:
 - (a) provide reports, including annual updates of your R&D Plan and estimates, and participate in reviews as described in this Agreement, and otherwise comply with the requirements of this Agreement in respect of the Programme and your claims for Funding;
 - (b) carry out the Programme in accordance with all legal requirements;
 - (c) procure that at all times none of your directors are persons who are prohibited from being a director by any applicable law;
 - (d) notify Callaghan Innovation as soon as reasonably possible after becoming aware of any breach of clause 1.2(c); and
 - (e) notify Callaghan Innovation as soon as reasonably possible if any changes in your business could adversely affect New Zealand or Callaghan Innovation's reputation.
- 1.3. You warrant that:
 - (a) you have not entered into any contractual arrangements or negotiations to receive public funding in respect of the Programme except as disclosed in your Application. If you enter into such contractual arrangements or negotiations before the contract end date specified in the Schedule ("Contract End Date"), you must promptly advise Callaghan Innovation, who may deem the matter to be a Change Event; and
 - (b) all claims submitted by you to Callaghan Innovation under this Agreement will have been certified correct by a duly authorised officer of your organisation.
- 1.4. You must be one of the following entity types:
 - (a) a company registered under the Companies Act 1993;
 - (b) a limited partnership registered under the Limited Partnership Act 2003; or
 - (c) a Maori incorporation or a trust established under the Te Ture Whenua Maori Act 1993, a trust established on behalf of Maori claimants to receive and manage assets as part of the settlement of a claim under the Treaty of Waitangi, a Maori statutory body, or a business that is controlled by one or more of these types of Maori entities,

but may not be an entity that is:

- (d) listed in Schedule 1 of the State Owned Enterprises Act 1986, Schedule 4A of the Public Finance Act 1989, or an entity established under or governed by the Education Act 1989,

Crown Research Institutes Act 1992, Local Government Act 2002, Local Government (Auckland Council) Act 2009, the New Zealand Public Health and Disability Act 2000, or the Crown Entities Act 2004; or an entity that is 50 per cent or more owned by one or more of those types of entities; or

- (e) in the opinion of Callaghan Innovation, likely to bring the reputation of Callaghan Innovation or the R&D grants programme into disrepute.

2. FUNDING

- 2.1. Callaghan Innovation will pay you the Funding in respect of your Eligible R&D Expenditure in accordance with the payment schedule set out in the Schedule ("Payments Schedule").
- 2.2. Callaghan Innovation may suspend payments of the Funding if you have not complied with this Agreement.
- 2.3. The amount of the Funding is exclusive of GST.
- 2.4. You are responsible for all taxation liabilities, ACC and other levies payable in relation to the Funding.
- 2.5. You must acknowledge, as appropriate and as requested by Callaghan Innovation, provision of Funding by Callaghan Innovation.
- 2.6. You may not claim Funding in respect of any Eligible R&D Expenditure incurred before the Contract Start Date.
- 2.7. Callaghan Innovation is not liable to pay Funding in respect of any Eligible R&D Expenditure incurred after the Contract End Date, and you may not claim any such Funding.

3. ELIGIBLE R&D EXPENDITURE

- 3.1. Subject to clause 3.2, your Eligible R&D Expenditure is your expenditure on the Programme that is for "**research**" or "**development**" as those terms are defined in the New Zealand Equivalent to International Account Standard 38 ("NZ IAS 38") and the New Zealand Financial Reporting Standard 13 ("NZ FRS 13"), up to the maximum total amount specified in the Schedule.
- 3.2. Your Eligible R&D Expenditure does not include any expenditure on the Programme that is not for "research" or "development" as defined in NZ IAS 38 and NZ FRS 13, including (but not limited to) expenditure:
 - (a) that is capitalised as an intangible asset for the purposes of NZ IAS 38;
 - (b) on research and development undertaken outside of New Zealand, unless it has been expressly permitted by Callaghan Innovation;
 - (c) that is funded by an enforceable levy that is paid to you by another entity, or paid by you to another entity;

- (d) on research and development funded by a grant or other payment you receive from an entity that is not part of the same consolidated group of entities as you (if applicable);
- (e) on engineering follow-through in an early phase of commercial production;
- (f) on activities related to the construction, relocation, rearrangement or start-up of facilities or equipment other than facilities or equipment solely used for your research and development;
- (g) on routine, ongoing efforts to refine, enrich, or otherwise improve on the quality of an existing product or process, or to make cosmetic or stylistic changes to it;
- (h) on routine design of tools, jigs, moulds and dies, or seasonal or other periodic design changes to existing products, except for expensed design activities involved in developing a new product or process;
- (i) on activities involved in ensuring that existing products or processes comply with statutory requirements or standards, and quality control, routine testing or trouble-shooting during commercial production, except for testing in search of significant product or process improvements;
- (j) on adapting an existing product or process to a particular customer's need or site;
- (k) on supporting, de-bugging, or making minor improvements to existing computer software;
- (l) on market research or surveys, market testing, market development or sales promotion, management studies, efficiency surveys, or the routine collection of information;
- (m) on protecting, licensing, selling or defending intellectual property or of acquiring or using external intangible assets (such as patent licences)
- (n) on interest expenses or lease payments of any kind, and any overheads that are not closely linked to research and development activities, except for finance, personnel, training, travel, administration, and library activities associated with the Programme, and reasonable costs associated with transportation, storage, cleaning, repairs, maintenance and security activities in relation to the Programme;
- (o) on prospecting or exploring for minerals, petroleum, natural gas, or geothermal energy;
- (p) on research in the social sciences, arts, or humanities; and
- (q) on providing independently audited financial statements as required by this Agreement.

4. INTELLECTUAL PROPERTY

- 4.1. Callaghan Innovation acknowledges that it is not the author of, or commissioning party for, any intellectual property arising from the Programme, and that it has no claim to ownership of any intellectual property rights arising from the Programme.

4.2. You must have in place intellectual property management practices and procedures in respect of the Programme that will ensure that you maximise the benefits arising from the Programme.

5. AUDIT

5.1. You must keep appropriate accounting and other records of your Eligible R&D Expenditure and your use of the Funding (including payslips, invoices, and receipts) and manage your records in accordance with recognised research and accounting best practice standards, so as to enable Callaghan Innovation to carry out an audit to determine whether you are complying or have complied with this Agreement (“**Audit**”).

5.2. Callaghan Innovation may undertake an Audit at any time between the Contract Start Date and the date that is 2 years after the Contract End Date.

5.3. If Callaghan Innovation undertakes an Audit, you must provide Callaghan Innovation or its authorised agents with any information that Callaghan Innovation reasonably requires to determine whether you are complying, or have complied, with this Agreement, including reasonable access to your staff, third parties and third party research contractors involved in the Programme, and premises and equipment used in respect of the Programme.

5.4. Callaghan Innovation will give you reasonable notice that an Audit is to be undertaken. The notice will specify who will conduct the Audit and the information and access that is required. Callaghan Innovation may request additional information and access from you during the Audit, and you must provide any information and access reasonably requested.

5.5. Responsibilities for meeting the costs of an Audit are as follows:

- (a) Callaghan Innovation is responsible for meeting the costs to Callaghan Innovation of carrying out the Audit; and
- (b) you are responsible for meeting the costs to you of providing access and information.

5.6. You will be given the opportunity to comment on the draft Audit report within a reasonable timeframe. Callaghan Innovation will finalise the draft Audit report after receiving and considering your comments (if any), and provide a copy of the final Audit report to you.

5.7. To avoid doubt, Callaghan Innovation may continue to exercise its rights under this Agreement (including any termination rights and any rights to seek repayment) despite commencing an Audit, and is not required to wait until the Audit is complete before doing so.

5.8. After the Audit report is finalised, if the Audit report has revealed a breach by you, Callaghan Innovation may do one or more of the following:

- (a) take no further action;
- (b) provide you with notice of the remedial actions you must take to address any issues identified in the Audit report (whether or not those issues constitute a breach of this Agreement), and any reports or information you must provide to Callaghan Innovation about those actions;

- (c) try to negotiate a variation of this Agreement with you;
 - (d) give you notice that Callaghan Innovation considers a Change Event has occurred pursuant to clause 9;
 - (e) terminate this Agreement; or
 - (f) recover all or part of the Funding pursuant to clause 11.
- 5.9. Subject to clause 5.10 you must carry out any remedial actions and provide any reports or information about those actions that are set out in the notice provided by Callaghan Innovation under clause 5.8 (b)5.7(b).
- 5.10. If you, acting reasonably, object to, or disagree with, all or any part of the remedial action required under clause 5.8 your objection or disagreement will be deemed a Change Event and managed in accordance with the Change Event provisions of this Agreement.
- 5.11. Callaghan Innovation may suspend payment of the Funding from the date of the notice of Audit if Callaghan Innovation considers that you may have breached this Agreement. In such case:
- (a) Callaghan Innovation will give notice that specifies that payment of the Funding has been suspended; and
 - (b) if the final Audit report shows that you have not breached this Agreement, Callaghan Innovation will recommence payment of the Funding, and provide an amount equivalent to the amount of Funding that would have accrued if the Funding had not been suspended. If there has been a material delay to the Programme as a result of the suspension of Funding under this clause, the matter will be deemed to be a Change Event.

6. REPORTING

- 6.1. Callaghan Innovation needs to monitor its provision of Funding for the Programme so that it can identify and report the benefits to New Zealand arising from the Programme, and take appropriate action if you do not comply with this Agreement.
- 6.2. You must provide Callaghan Innovation or its authorised agents:
- (a) at any time between the Contract Start Date and the date that is 3 years after the Contract End Date, with the reports specified in the reporting schedule specified in the Schedule; or
 - (b) Reports as requested from time to time. Such reports are to be provided within 10 Business days from the request. Failure to provide a report within 10 Business days will result in Callaghan Innovation conducting a Review pursuant to clause 7.
- 6.3. You must advise Callaghan Innovation of any significant issues and risks relating to the Programme or this Agreement as they arise, which may include:
- (a) loss of critical resources (including loss of people, loss of co-funding, or infrastructure); or
 - (b) the scientific or technical approach changing significantly; or

- (c) consents, approvals, licences and permits required by you cannot be obtained, have expired or are revoked; or
- (d) significant issues with, or changes to, end-user engagement; or
- (e) changes that materially reduce the benefit to New Zealand from the Programme (e.g. contracts or arrangements with third parties offshore); or
- (f) scientific, technical or financial fraud; or
- (g) material changes to your organisation, including changes to your organisation's core strategy/directions; or
- (h) anything that puts your ability to undertake the Programme at serious risk.

6.4. All reports and information provided by you must be:

- (a) provided in the form and manner specified by Callaghan Innovation from time to time;
- (b) accurate; and
- (c) provided in a timely manner.

7. REVIEW

7.1. Callaghan Innovation may at any time between the Contract Start Date and the date that is 3 years after the Contract End Date, carry out a review of the Programme and Callaghan Innovation's investment in the Programme ("**Review**"). You must participate in any Reviews as reasonably required by Callaghan Innovation, including by providing information requested by Callaghan Innovation.

7.2. If a Review is carried out before the Contract End Date and is not satisfactory to Callaghan Innovation, the matter may be considered and managed in accordance with the Change Event provisions of this Agreement.

8. CONFIDENTIALITY

8.1. You acknowledge that Callaghan Innovation is required to release information relating to this Agreement, its investment in the Programme, the progress of the Programme, and the benefits to New Zealand from the Programme, from time to time.

8.2. You agree that Callaghan Innovation may release the following information relating to this Agreement, the Programme:

- (a) your name and contact details;
- (b) the Contract ID;
- (c) the title of the Programme;
- (d) the fund from which Funding for the Programme is provided;

- (e) the relevant sector;
- (f) the total amount of Funding paid;
- (g) the total amount of Funding payable over the duration of this Agreement;
- (h) the year Funding was approved; and
- (i) statistics relating to the Programme in aggregated form.
- (j) If Callaghan Innovation has terminated this Agreement pursuant to clause 10.3 or 10.4, a summary of the reasons for the termination.

8.3. You acknowledge that Callaghan Innovation may release information relating to this Agreement to its duly appointed agents and advisors, the Ministry of Business, Innovation, and Employment, Ministry for Primary Industries and New Zealand Trade and Enterprise.

8.4. Except as provided for in clauses 8.2 and 8.3, Callaghan Innovation will not release information relating to this Agreement unless Callaghan Innovation is obliged to release that information under the Official Information Act 1982, the Privacy Act 1993, at law, under any regulation or to provide an answer to any parliamentary questions, meet any parliamentary requirements, or provide information to a Minister.

8.5. Callaghan Innovation will advise you if it receives a request under the Official Information Act 1982 or the Privacy Act 1993 for any information relating to this Agreement, and will consult with you before responding to the request.

9. CHANGE EVENTS

9.1. A change event ("**Change Event**") occurs if either of us receives new information, or an event occurs or is likely to occur, that materially affects or is likely to materially affect this Agreement or the Programme, and includes without limitation the following:

- (a) an event that prevents, or is likely to prevent, either of us from being able to meet our obligations under this Agreement;
- (b) an event, including changes to your governance, senior management or business structure, or an actual or likely change in your ownership or sale of any of your assets, which materially adversely affects, or is likely to materially adversely affect the anticipated benefits for New Zealand of the Programme, including planned research and development activity in New Zealand, and the timing of those benefits; or
- (c) Callaghan Innovation determines, at any time, that your actual Eligible R&D Expenditure is or is likely to be significantly different from the amount of Eligible R&D Expenditure that you anticipated investing in the Programme that is specified in your Application.

9.2. If a Change Event occurs:

- (a) we will immediately advise each other by notice of the Change Event; and

- (b) we will discuss our options to resolve the Change Event in good faith, which may include taking no action, negotiating a variation to this Agreement, or terminating this Agreement; and
- (c) Callaghan Innovation may suspend payment of the Funding if in the reasonable opinion of Callaghan Innovation your ability to carry out the Programme is adversely affected.

9.3. In discussing our options to resolve a Change Event:

- (a) we will act in good faith and in a way that is consistent with the mutual interest between us in the delivery of the Programme, the anticipated benefit to New Zealand from the Programme and maintaining research capability critical to New Zealand; and
- (b) we, or Callaghan Innovation on its own account, may undertake a Review of the Programme to help Callaghan Innovation decide how to respond to the Change Event.

9.4. If we agree to negotiate in good faith a variation to this Agreement, the variation may include, without limitation, changes to the Programme, the duration of the Programme, or the Funding.

9.5. If we are unable to resolve a Change Event by 1 month after the date of the notice given under clause 9.2(a), either of us may immediately terminate this Agreement by notice.

9.6. Nothing in this clause prevents either of us from exercising our powers under clause 10.

10. TERMINATION AND REDUCTION OR SUSPENSION OF FUNDING

10.1. This Agreement may be terminated by either of us at any time by giving 2 months' notice to the other party.

10.2. If funding allocated to Callaghan Innovation to cover the Funding under this Agreement is reprioritised, reduced, suspended, or terminated (whether because funding to the relevant Government appropriation is altered, reprioritised, ceased or otherwise), Callaghan Innovation may do any of the following:

- (a) reduce the Funding;
- (b) suspend the Funding; or
- (c) terminate this Agreement.

10.3. Either of us may terminate this Agreement immediately by notice to the other party if the other party is in breach of its obligations under this Agreement.

10.4. Callaghan Innovation may terminate this Agreement immediately by notice to you if you:

- (a) use some or all of the Funding other than as set out in this Agreement, including that there is, in Callaghan Innovation's reasonable opinion, misappropriation or fraud in relation to the Funding;

- (b) give (or have given) any information, representation, or statement to Callaghan Innovation that is misleading or inaccurate in any material respect;
 - (c) fail to provide independently audited financial statements or accounts or verification of your R&D expenditure certified by an independent chartered accountant within 6 months of the end of each financial year and within 6 months of the Contract End Date.
 - (d) claim Funding that you are not entitled to claim under this Agreement, including claiming for expenditure that is not Eligible R&D Expenditure ;
 - (e) enter into a contract or an arrangement that, in the reasonable opinion of Callaghan Innovation, materially reduces the benefit to New Zealand anticipated from the Programme without the prior written approval of Callaghan Innovation; or
 - (f) become, or are presumed to be, bankrupt or insolvent, are wound up, have a receiver, manager or administrator appointed, or go into liquidation or receivership; or
 - (g) are in breach of your undertaking under clause 1.2(c) and such breach is not remedied within 20 Business Days of the breach occurring.
- 10.5. If Callaghan Innovation is entitled to terminate this Agreement under clause 10.4(c), it may suspend the Funding (without prejudice to its right to subsequently terminate).
- 10.6. If Callaghan Innovation terminates this Agreement, Callaghan Innovation:
- (a) is not required to pay Funding suspended or withheld from you under this Agreement; and
 - (b) may, at its discretion, pay an amount to you for Programme Costs incurred by you before the date of the notice of termination for which Funding has not been paid by Callaghan Innovation.
- 10.7. If Callaghan Innovation reduces, suspends, or reprioritises any Funding under clause 10.2, you may immediately by notice terminate this Agreement.
- 10.8. Termination of this Agreement is without prejudice to the rights and obligations of either of us that accrued up to the date of termination.

11. RETURN AND REPAYMENT OF FUNDING

- 11.1. If this Agreement is terminated for any reason you must return to Callaghan Innovation all Funding that has not been spent or for which contractual liabilities have not yet been reasonably incurred as at the date of the notice of termination.
- 11.2. If this Agreement is terminated for any reason (unless termination occurred as a result of a breach by Callaghan Innovation) Callaghan Innovation may by notice require you to, and in such event you must, repay some or all of the Funding for the Programme, such amount to be determined by Callaghan Innovation, together with interest on that amount calculated at the Official Cash Rate of the Reserve Bank of New Zealand plus 5%, from the date you were paid the Funding to the date you repay the amount determined by Callaghan Innovation.

- 11.3. If, within 3 years of the Contract End Date or the date of termination of this Agreement (whichever is the earlier), you enter into a contract or an arrangement that, in the reasonable opinion of Callaghan Innovation, materially reduces the benefit to New Zealand anticipated from the Programme, Callaghan Innovation may by notice require you to, and in such event you must, repay some or all of the Funding for the Programme, such amount to be determined by Callaghan Innovation, together with interest on that amount calculated at the Official Cash Rate of the Reserve Bank of New Zealand plus 5% from the date you were paid the Funding to the date you repay the amount determined by Callaghan Innovation.
- 11.4. For the purpose of clauses 10.4(e) and 11.3, the benefit to New Zealand anticipated from the Programme is deemed to be materially reduced if, in the reasonable opinion of Callaghan Innovation:
- (a) the likelihood of you developing a more stable and substantial New Zealand-based R&D programme is reduced;
 - (b) the size of or value of your R&D programme materially reduces; or
 - (c) your R&D programme is carried on outside of New Zealand.

12. INDEMNITY

- 12.1. You indemnify Callaghan Innovation against any claim, liability, loss or expense, including without limitation, damages, legal fees, costs, and disbursements, brought or threatened against or incurred by Callaghan Innovation ("Loss"), caused by an act or omission by you and arising from this Agreement, except to the extent that the Loss was caused by an act or omission of Callaghan Innovation (other than the provision of Funding by Callaghan Innovation. If any third party makes a claim or notifies an intention to make a claim against Callaghan Innovation ("Claim Made"), or Callaghan Innovation incurs a Loss that may reasonably be considered likely to give rise to a liability under this indemnity:
- (a) Callaghan Innovation will give notice to you of any Claim Made or Loss for which indemnification is sought; and
 - (b) Callaghan Innovation will provide any reasonable assistance which you may request for the defence of any Claim Made in respect for which indemnification is sought; and
 - (c) you have the right to control the defence or settlement of any such Claim Made at your cost; and
 - (d) Callaghan Innovation has the right to participate in, but not control, any litigation in respect of the Claim Made with counsel of its choosing, such counsel to be at Callaghan Innovation's expense.

Provided that compliance by Callaghan Innovation with the above requirements is not a condition of your liability under this indemnity.

12.2. Your liability under this indemnity is limited to the maximum Funding Amount specified in the Schedule to this Agreement.

13. ENTIRE AGREEMENT

13.1. We agree that this Agreement, including the schedules, and any documents incorporated by reference, represents the entire agreement between us.

14. NOTICES

14.1. Any notice given under this Agreement will be given by post or by email.

14.2. A notice given by email will be deemed to have been received 1 Business Day after sending and a notice given by post will be deemed to have been received 3 Business Days after posting.

14.3. For the purposes of this Agreement, "**Business Day**" means any day not being a Saturday, a Sunday, or a public holiday under the Holidays Act 2003.

14.4. A notice to Callaghan Innovation must be sent to the following address, or to any other address advised by Callaghan Innovation from time to time:

(a) by post, to Callaghan Innovation, PO Box 11529 Manners Street, Wellington; or

(b) by email, to the Manager at investmentsupport@callaghaninnovation.govt.nz.

14.5. A notice to you will be sent to the person and to the address set out in the Schedule.

15. SURVIVAL OF CLAUSES

15.1. Expiry or termination of this Agreement for any reason does not affect the validity and enforceability of this clause, clause 5 (Audit), clause 6 (Reporting), clause 7 (Review), clause 8 (Confidentiality), clause 11 (Return and Repayment of Funding), clause 12 (Indemnity), clause 14 (Notices), clause 20 (Governing Law) clause 21 (Waiver), and the provisions of the Payment Schedule and any Special Conditions set out in the Schedule which that, by their nature, continue to be relevant (or expressly survive termination).

16. FOREC MAJEURE

16.1. Neither of us is responsible to the other for delay or failure in performance of any of the obligations imposed by this Agreement if such failure is caused by an event that is beyond the reasonable control and occurs without the fault or negligence of the delaying or failing party.

16.2. If either party is unable to perform its obligation under this Agreement because of an event of the type described in clause 16.1 for a period of 2 months or more, the other party may terminate this Agreement immediately by notice.

17. NATURE OF RELATIONSHIP

17.1. This Agreement does not create a relationship between us of employer and employee, principal and agent, partners, or joint venturers.

18. VARIATIONS

- 18.1. The terms of this Agreement are varied as set out in the Schedule (if applicable).
- 18.2. No modification, variation, extension, or waiver of this Agreement, including any schedule, will be effective and binding on us unless made in writing and signed by both of us.

19. ASSIGNMENT & TRANSFER

- 19.1. You may not assign or otherwise transfer your rights and obligations under this Agreement to a third party.
- 19.2. Any change affecting the control of your organisation will be deemed a transfer and an assignment.

20. GOVERNING LAW

- 20.1. This Agreement will be interpreted in accordance with the laws of New Zealand.
- 20.2. Any legal action or proceeding arising out of or in connection with this Agreement that is commenced by Callaghan Innovation against you may be brought in the courts of New Zealand, or in any other country:
- (a) Under the laws of which you are legally established; or
 - (b) In which you have a place of business at the time the proceedings are commenced; or
 - (c) in which you have any property situated at the time the proceedings are commenced.
- 20.3. By your execution of this Agreement; you:
- (a) Accept, for yourself and your property, generally and unconditionally, the non-exclusive jurisdiction of such courts;
 - (b) Irrevocably waive your rights of immunity which you or your property may have at the time;
 - (c) irrevocably waive any objection you may have at any time to any action or proceeding in any such court on the grounds of venue or inappropriate or inconvenient forum; and
 - (d) consent to service of process in any manner permitted by law.
- 20.4. Any legal action or proceeding arising out of or in connection with this Agreement that is commenced by you must be brought in the courts of New Zealand, unless Callaghan innovation has previously commenced proceedings against you in a court of another country, in which case your claim may be brought in that court.
- 20.5. If you are not a company or other legal entity established under New Zealand law:
- (a) You shall maintain an agent or representative in New Zealand to accept service of any document required to be served on you in relation to proceedings under or in connection with this Agreement which are commenced in the courts of New Zealand, or in the courts of any other country;

- (b) You appoint

Name:

Whose address is:

as its agents for service and undertakes to notify Callaghan Innovation promptly of any change of address of a current agent or representative and of the name and address of any substitute agent or representative; and

- (c) Any document shall be sufficiently served on you if delivered to the most recently notified agent or representative at its notified address.

20.6. Any document required to be served on you in relation to proceedings under or in connection with this Agreement which are commenced in the courts of New Zealand, or in the courts of any other country, may also (if permitted under the law of that country) be served by:

- (a) Delivering the document to the deliver address specified in the Schedule; or
- (b) Sending the document by email to the email address specified in the Schedule.

20.7. The methods of service set out in this clause 20.6 are in addition to, and do not limit or restrict, any other lawful manner in which documents may be served you.

21. WAIVER

21.1. Failure or omission by either of us at any time to enforce or require strict or timely compliance with a term or condition of this Agreement will not affect or impair the term or condition in any way or any rights or remedies either of us may have in respect of any breach of the term or condition.

22. PARTIAL INVALIDITY

22.1. The illegality, invalidity, or unenforceability of a provision of this Agreement under any law, does not affect the legality, validity, or enforceability of any other provision of this Agreement.

22.2. If any clause of this Agreement is held to be unenforceable or in conflict with the law, the invalid or unenforceable clause will be replaced with a clause, which as far as possible, accomplishes the original purpose of the clause.

SCHEDULE
Agreement Details – R&D Growth Grant

Contractor's Details:

Name	
Address	
Contact person	
Contact phone	
Email	

Approval Details:

Contract ID	
Application ID	
Programme Title	
Eligible R&D Expenditure	Up to a maximum of \$25,000,000 (excluding GST) in each year starting on the Contract Start Date for the first year, and starting on the anniversary of the Contract Start Date in every subsequent year (" Contract Year ").
Funding Amount	Up to a maximum of \$5,000,000 (excluding GST) in each Contract Year
Funding Rate	20%, which is the percentage of your Eligible R&D Expenditure incurred by you that Callaghan Innovation will pay, up to the Funding Amount
Contract Start Date	
Contract End Date	
Variations to this Agreement	There are no variations to the general terms set out in this agreement.
Payment Schedule	<ol style="list-style-type: none"> 1. Callaghan Innovation will pay you quarterly in arrears on receipt of the End of Quarter Report which includes your claim for that quarter and an invoice. 2. Your invoice must reflect 10% retention of the payment for each quarterly claim. 3. Upon receipt of a Financial Year End Report and an invoice Callaghan Innovation will make a final payment for that financial year equal to 20% of certified Eligible R&D Expenditure less any amount already paid for that financial year. 4. The last quarterly claim for the contract period and any outstanding retention, under paragraph 2 above, at Contract End Date will be withheld from the business until receipt and validation of the End of Contract Report and an invoice.
Reporting Schedule	<ol style="list-style-type: none"> 1. You must provide an End of Quarter Report within 2 months of the end of each quarter for each of your financial years during the contract term that includes: <ol style="list-style-type: none"> i. Your actual Eligible R&D Expenditure during the quarter, ii. Status update on the performance of your Programme, iii. An updated claims spreadsheet; and iv. Any matter that may affect your ability to carry out the Programme. 2. Within 6 months of the end of each of your financial years during the term of the contract you must provide a Financial Year End Report that includes:

	<ul style="list-style-type: none"> i. An independently audited financial statement that confirms that you are claiming Funding only in respect of Eligible R&D Expenditure, is in the form specified by Callaghan Innovation, and is certified by an independent chartered accountant ii. An update of your R&D Plan and estimates, and iii. An updated claims spreadsheet. <p>Failure to do so may result in suspension of payment of the Funding or termination of this Agreement pursuant to clause 10.</p> <p>Surveys</p> <p>1. You must, if requested by Callaghan Innovation, complete a survey about the Programme, which may require you to provide information about the benefits to New Zealand arising from the Programme.</p>
Final Report	You must provide an End of Contract report together with your final invoice and independently audited financial statements, no later than 6 months after the Contract End Date.

Special Conditions:

	Condition	Condition type	Due date	Date satisfied